FTSE shows the drugs do work

The jump in Europe's third-largest drugmaker’s share price follows the announcement that David Brennan, who oversaw the marketing of the company's best-selling Nexium ulcer treatment as head of U.S. operations, will replace Chief Executive Tom McKillop. McKillop will leave the company at the end of the year. Other gains today include Rolls-Royce which soared more than 10% after it boosted its dividend and half-year profits. The group’s stock gained 30p to 342p after the company announced to investors that it would be providing a 5% increase in the interim dividend to 3.34p per share –...